SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

CALENDAR UPDATE

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
flipper44 Member Profile
Member Level 
Followed By 69
Posts 9,867
Boards Moderated 0
Alias Born 11/14/13
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/16/2017 5:28:13 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/22/2017 5:11:32 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/22/2017 4:18:34 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/22/2017 8:58:57 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 9/11/2017 2:46:27 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 9/11/2017 2:41:35 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/21/2017 4:40:00 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 8/15/2017 4:12:02 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/8/2017 5:28:51 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/7/2017 5:24:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 8/7/2017 5:19:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/7/2017 1:14:16 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/26/2017 3:21:58 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/21/2017 5:17:26 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/29/2017 4:27:47 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/27/2017 5:02:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/19/2017 5:20:48 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/13/2017 5:08:50 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 6/1/2017 10:28:04 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/31/2017 7:37:55 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/26/2017 5:23:00 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 5/17/2017 11:54:01 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/15/2017 5:35:32 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/25/2017 5:12:52 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 4/17/2017 5:26:07 PM
flipper44 Member Level  Wednesday, 07/05/17 09:18:42 AM
Re: flipper44 post# 123275
Post # of 139198 
CALENDAR UPDATE

Additions or changes below in red.

March 7 -- About 3 million in loans received -- due in 6 months (+ interest) or sooner. Changes in this post made after reading "refinements" from Jerry.
March 17 -- 7.5 (Effectively 6.7 million after expenses according to Jerry) million raise. (Closed on March 22nd)
March 27 -- DCVax Advanced Method (aka: B+(?)) International Publication Date of International Patent Application for "METHODS RELATING TO ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS" -- DD Courtesy of Smokey
March 28 -- Yonemura v. Powers recorded conference call. (Stayed to July 28 for "final resolution")
March 30 -- Last day for companies at ASCO to get any "late breaking abstract" data in.
March 30 -- Dr. Schwartz inaccurately tweets (with glee) NWBO withdrew their NWBO ASCO booths.
March 30/31 -- 6 Cognate jobs (with prior various original posting dates) reposted on Monster.com
March 31 -- Payment by NWBO due -- 500k (or sooner upon request)(paid)
March 31 -- Lerner v. NWBO case dismissed in favor of NWBO. (Approximately 19.3 month old case) (Info: Courtesy of Senti)

April 1 -- Dr. Prins speaks at AACR conference.
April 3 -- Job listing: Manager, Validation Services at Cognate Bioservices.
April 4 -- Two business days after Lerner suit dismissed and five business days after Yonemura case set for "final resolution" this summer, AF writes hit article against NWBO regarding (no longer existing) partial clinical hold on screening. Additionally, AF criticizes NWBO AACR booth, booth location and Dr. Bosch. Dr. Schwartz also criticizes (and tweets) AACR booth with joy -- claims no one there to answer questions -- Even though AF questioned Dr. Bosch.
April 5 -- India FDA approves autologous dendritic therapy for prostate, ovarian, lung and colorectal cancer. (Info courtesy of ForumReader35)
April 17 --10K filed
April 18 -- Since March 31, five Cognate job postings the listed and/or relisted have either been filled (or simply removed.)
April 19 -- Payment by NWBO due -- 2.3 million (some might be due sooner upon request) (paid).
April19 -- Payment by board (lenders) on 2.3 million through loan financing.
April 19 -- ASCO Titles leaked by ASCO website one day early. http://www.investorvillage.com/smbd.asp?mb=16353&mn=78709&pt=msg&mid=17081359
April 20 -- ASCO titles for Regular and LBA released. No abstracts related to DCVax.
April 24 -- Bear attack, preceded over the weekend by unsubstantiated claim of PFS futility.
April 25 -- Announcement of loan financing by Board members that occurred on April 19, 2017 to pay off 2.3 million in notes owed.

May 5 -- Since March 31/April 4, seven of seven Cognate job postings listed and/or relisted have either been filled (or perhaps simply removed.)
May 5 -- One million dollar loan (aka: equivalent to six-and-a-half million shares). Due on June 30, 2017. (Due Diligence courtesy of Omair92 & Bioaddict )
May 9 -- Likely final vote on FDA Commissioner confirmation -- Due Diligence courtesy of Sentimentstocks.
May 9 -- Scott Gottlieb confirmed as new FDA Commisioner.
May 10 -- ESMO regular abstract deadline.
May 15 -- Woodford Fund confirms it is still holding NWBO in its Patient Capital Trust portfolio as of April 30, 2017. (Due Diligence Courtesy of TiltMyBrain)
May 15 -- 1st Quarter 10Q filing due. (Due Diligence reminder courtesy of Kabunushi)
May 15 -- 1st Quarter 10Q filed. SentimentStocks pointed out the 10Q notes that NWBO is now moving forward with process validation work.
May 17 -- Regular abstracts released by ASCO
May 17 -- Notice of exempt offering of securities filed with SEC.
May 17 -- UK's NICE confirms developing a guideline on DCVax-L for treating newly diagnosed glioblastoma -- albeit in early stages. Due Diligence Courtesy of CherryTree.
May 20 -- Payment by NWBO due -- 2.5 million (paid)
May 22, 2017 -- Security Purchase Agreement hold on PFS data release lifted.
End of May, or possibly later, rGBM combination trial to initiate. NOW moved to August.

Maybe June or later -- 233 events
June 2-6 -- ASCO. LBAs released
June 5 -- Dr. Marnix Bosch discusses DCVax at ASCO's Industry Expert Theater @ 3:00.
June 5 -- Dr. Marnix Bosch notes currently 231 patient OS events (100 patients still alive), and 233 events expected by mid July 2017. He notes OS eventing is slower than anticipated at this time.
Dr. Bosch also notes Investigators already working on a publication for the DCVax-L trial. Median Length of time patients have been enrolled in the DCVax-L trial is 37 months. Dr. Bosch is preparing for a sarcoma trial for DCVax-Direct soon and plans on incorporating approved checkpoint inhibitors in some DCVax-Direct trials. In the Phase I DCVax-Direct trial, 23% of patients exceeded two years OS, and 18% have exceeded 30 months. In the info arm for DCVax-L, 40% of patients lived past about three years in the indeterminate arm and 24% have lived past four years in the same arm.
June 12 -- SNO (Society for NeuroOncology) regular abstract deadline.
Approx. June 17 -- Deadline to exercise 3 month warrants? Up to $21.6 million cash received (or none at all)
June 20 -- Payment by NWBO due -- 5.5 million (Paid)
June 22 -- Announcement: "This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondholders entered into in March". (Due Diligence by John, and premonition of sorts by JDHeart smile)
June 30 -- Repayment on 1 million dollar loan due.

July 19 -- LBA deadline ESMO
July 28 -- Yonemura v. Powers, "Final Resolution."

August -- Scheduled start of DCVax-L recurrent GBM combo trial.
Aug 1 -- SITC regular abstract deadline.
Aug 5 -- Last screening/recruitment was TWO YEARS (24 months) prior to this date in the phase III DCVax-L trial.
Aug 31 -- August 31, 2017 11:45 Dendritic Cell Immunotherapy for Solid Tumors, Marnix Bosch, Ph.D., CTO, Northwest Biotherapeutics (Due Diligence Courtesy of Forum Redaer)

Sept 1 -- Late Breaking Abstracts Due for SNO Conference. (Society for NeuroOncology) (Due Diligence courtesy of Antihama)
Sept 7 -- Approximately 3 million (+ interest) in loan repayments by NWBO due (or sooner upon request).
Sept 8-12 ESMO Congress
Sept 27 -- LP speaks at SMI Cancer Vaccine conference (Due Diligence Courtesy of John1045)

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist